HuGE Literature Finder
Records 1-5
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology 2018 01 29 (1): 139-144. Overman M J, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz |
CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Jun 20 (12): 3261-71. Cleven Arjen H G, Derks Sarah, Draht Muriel X G, Smits Kim M, Melotte Veerle, Van Neste Leander, Tournier Benjamin, Jooste Valerie, Chapusot Caroline, Weijenberg Matty P, Herman James G, de Bruïne Adriaan P, van Engeland Man |
B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP).
PloS one 2011 6 (6): e21102. Schernhammer Eva S, Giovannucci Edward, Baba Yoshifumi, Fuchs Charles S, Ogino Shu |
A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.
Gastroenterology 2009 Nov 137 (5): 1609-20.e1-3. Nosho Katsuhiko, Kure Shoko, Irahara Natsumi, Shima Kaori, Baba Yoshifumi, Spiegelman Donna, Meyerhardt Jeffrey A, Giovannucci Edward L, Fuchs Charles S, Ogino Shu |
Coding region polymorphisms in the CHFR mitotic stress checkpoint gene are associated with colorectal cancer risk.
Cancer letters 2008 Feb 260 (1-2): 170-9. Kang Hio Chung, Kim Il-Jin, Jang Sang-Geun, Hong Seung-Hyun, Hwang Jung-Ah, Shin Hai-Rim, Park Jae-Ga |
- Page last reviewed:Oct 1, 2020
- Page last updated:Mar 05, 2021
- Content source: